Sensitizing HR-proficient cancers to PARP inhibitors

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Molecular & Cellular Oncology

• Publication date

  2017-11-02

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1080/23723556.2017.1299272PMID 29209638PMCID PMC5706951
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.

  2016cited by this paper
• Poly (ADP-ribose) polymerase inhibitors: recent advances and future development.

  2015cited by this paper
• Characterization of Human Cyclin-Dependent Kinase 12 (CDK12) and CDK13 Complexes in C-Terminal Domain Phosphorylation, Gene Transcription, and RNA Processing

  2015cited by this paper
• Ovarian Cancer-associated Mutations Disable Catalytic Activity of CDK12, a Kinase That Promotes Homologous Recombination Repair and Resistance to Cisplatin and Poly(ADP-ribose) Polymerase Inhibitors*

  2014cited by this paper
• Molecular Pathways Molecular Pathways : How Can BRCA-Mutated Tumors Become Resistant to PARP Inhibitors ?

  2014cited by this paper
• BRCA1 Pathway Function in Basal-Like Breast Cancer Cells

  2014cited by this paper
• The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes.

  2011cited by this paper
• Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor

  2010cited by this paper
• 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers

  2010cited by this paper
• Heterogenic Loss of the Wild-Type BRCA Allele in Human Breast Tumorigenesis

  2007cited by this paper

• The potential of the South African plant Tulbaghia Violacea Harv for the treatment of triple negative breast cancer

  2025cites this paper
• Caspase 3 and caspase 7 promote cytoprotective autophagy and the DNA damage response during non-lethal stress conditions in human breast cancer cells

  2025cites this paper
• Precision Medicine for BRCA/PALB2-Mutated Pancreatic Cancer and Emerging Strategies to Improve Therapeutic Responses to PARP Inhibition

  2022cites this paper
• Therapeutic Advances in Oncology

  2021cites this paper
• Response prediction biomarkers and drug combinations of PARP inhibitors in prostate cancer

  2021cites this paper
• Exploiting replicative stress in gynecological cancers as a therapeutic strategy

  2020cites this paper
• Potential biomarkers of Poly (ADP-ribose) polymerase inhibitors for cancer therapy

  2018cites this paper